SCHEMBL20840310

SCHEMBL20840310

O=C(O)c1cccc(N2N=C(C(F)(F)F)C(=Cc3ccc(-c4ccc(Cl)c(C(=O)O)c4)o3)C2=O)c1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERO1A Q96HE7 2/20 0.77
KDM1A O60341 1/20 0.77
MAOA P21397 1/20 0.77
MAOB P27338 1/20 0.77
XPA P23025 12/20 0.72
CTSB P07858 1/20 0.69
EP300 Q09472 1/20 0.67
KDM4E B2RXH2 1/20 0.61
MEN1 O00255 1/20 0.61
POLB P06746 1/20 0.61
MAPT P10636 1/20 0.61
THRB P10828 1/20 0.61
APEX1 P27695 1/20 0.61
RECQL P46063 1/20 0.61
KMT2A Q03164 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
PTPN1 P18031 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20840309 1.00 ERO1A (0.77) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL20848009 1.00 ERO1A (0.77) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL20840344 0.90 XPA (0.73) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL20840345 0.90 XPA (0.73) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL22219633 0.90 XPA (0.73) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL20840299 0.88 XPA (0.81) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL20848003 0.88 XPA (0.81) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL20840300 0.88 XPA (0.81) ERO1AKDM1AMAOAMAOBXPA
SCHEMBL20840316 0.87 EP300 (0.87) XPAEP300KDM4EMEN1POLB
SCHEMBL14426455 0.87 EP300 (0.87) XPAEP300KDM4EMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3684354-B1 XPA INHIBITOR COMPOUNDS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2023-11-15 EP disclosed
US-11207296-B2 XPA inhibitor compounds and their use INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2021-12-28 US disclosed
EP-3684354-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE Indiana University Research and Technology Corporation (US) 2020-07-29 EP disclosed
US-20200222367-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-07-16 US disclosed
WO-2019060260-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200222367-A1 XPA INHIBITOR COMPOUNDS AND THEIR USE XPOT, XPA, ERCC4 ERO1A 926/4885KDM1A 2277/4885MAOA 3248/4885
US-11207296-B2 XPA inhibitor compounds and their use XPOT, XPA, ERCC4 ERO1A 926/4885KDM1A 2277/4885MAOA 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.